New drug combo aims to keep advanced lung cancer in check
NCT ID NCT07110103
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding golidocitinib to standard PD-1 inhibitor maintenance therapy can help people with extensive-stage small cell lung cancer (SCLC) stay progression-free longer. Twenty adults who have not yet been treated for their advanced SCLC will receive the drug combination after initial chemotherapy. The study is open-label and single-arm, meaning everyone gets the experimental treatment, and it is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
golidocitinib (AZD4205) combined with PD-1 inhibitors
What this could lead to
If successful, this could offer a new maintenance treatment option to help control extensive-stage small cell lung cancer and potentially extend the time before the disease worsens.
What could go wrong
This is a small, early-phase (Phase 2) study with only 20 participants, so results may not apply broadly. The combination therapy may cause side effects or fail to improve outcomes compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xinqiao Hospital, Third Military Medical University
RECRUITINGChongqing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••